Centogene

47 articles with Centogene

• CENTOGENE Signs Memorandum of Understanding with Republic of Tajikistan

  8/1/2019

  Supporting rare disease diagnosis, education, and clinical research

• CENTOGENE Reveals Growth of Rare Hereditary Disease Knowledge Base

  7/1/2019

  CENTOGENE revealed the growth in its knowledge-base of rare hereditary diseases.

• CENTOGENE Launches PICOPglobal: Two Year Global Study on Colon- and Pancreas-Carcinoma

  6/27/2019

  Driving personalized, immune-based therapy to target patients’ own immune responses

• Four Year Study Reveals Importance of Lyso-Gb1 in Monitoring Gaucher Disease Patients

  6/25/2019

  CENTOGENE biomarker measures lyso-Gb1 levels in children

• CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution

  6/18/2019

  Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database

• CENTOGENE Launches Research Study to Unravel the Genetics of Hypophosphatasia

  6/13/2019

  Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia

• CENTOGENE iPSC Technology Solutions to Support Disease Modeling

  5/28/2019

  In a whitepaper released, CENTOGENE provided an update on its induced pluripotent stem cells program.

• CENTOGENE Welcomes Germany’s Chancellor Dr. Angela Merkel

  5/23/2019

  CENTOGENE welcomed Germany’s Chancellor Dr. Angela Merkel to its headquarters together with Manuela Schwesig, Minister-President of Mecklenburg-Vorpommern.

• CENTOGENE Launches Two Year Global Parkinson’s Disease Study

  5/13/2019

  One of the largest, most ethnically diverse studies of Parkinson’s disease to uncover the genetic basis of one of the most common neurodegenerative disorders

• CENTOGENE Expands Executive Leadership Team

  5/9/2019

  CENTOGENE announced the expansion of its executive leadership team with the appointment of Sun Kim in Boston, MA asChief Strategy & Investor Relations Officer.

• 

  1Q2019 Life Science Growth Announcements

  4/18/2019

  In the first quarter of 2019, more than 30 life science companies* announced  expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.

• CENTOGENE Appoints AI Industry Leader Dr. Carsten Ullrich as Director of Artificial Intelligence

  4/17/2019

  Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners

• CENTOGENE Launches CentoMetabolic™ Panel for Integrated Multiomic Testing for Metabolic Diseases

  4/10/2019

  Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions

• CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman

  4/2/2019

  CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.

• CENTOGENE Announces Strategic Collaboration with Sarepta Therapeutics

  2/28/2019

  Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)

• CENTOGENE Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics

  1/30/2019

  Since NGS introduces a relevant number of false positives and false negatives, CENTOGENE has determined how to optimize the use of orthogonal Sanger sequencing of variants in parallel when looking at borderline cases.

• CENTOGENE Expands Clinical Studies Team in U.S.

  1/28/2019

  Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development

• CENTOGENE Receives Prestigious Re-Accreditation by College of American Pathologists

  1/24/2019

  CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year

• CENTOGENE Provides Corporate and Business Unit Update

  1/8/2019

  2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases - driving momentum into 2019

• CENTOGENE and Chiesi Germany Sign Strategic Alliance in Lysosomal Storage Disorders

  12/10/2018

  CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development